Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

BMC Medicine (Impact Factor: 7.28). 01/2013; 11(1):17. DOI: 10.1186/1741-7015-11-17
Source: PubMed

ABSTRACT Methotrexate (MTX) is the central drug in the management of rheumatoid arthritis (RA) and other immune mediated inflammatory diseases. It is widely used either in monotherapy or in association with other synthetic and biologic disease modifying anti-rheumatic drugs (DMARDs). Although comprehensive clinical experience exists for MTX and synthetic DMARDs, to date it has not been possible to preview correctly whether or not a patient will respond to treatment with these drugs. Predicting response to MTX and other DMARDs would allow the selection of patients based on their likelihood of response, thus enabling individualized therapy and avoiding unnecessary adverse effects and elevated costs. However, studies analyzing this issue have struggled to obtain consistent, replicable results and no factor has yet been recognized to individually distinguish responders from nonresponders at treatment start. Variables possibly influencing drug effectiveness may be disease-, patient- or treatment-related, clinical or biological (genetic and nongenetic). In this review we summarize current evidence on predictors of response to MTX and other synthetic DMARDs, discuss possible causes for the heterogeneity observed and address its translation into daily clinical practice.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Although methotrexate (MTX) is the most used drug in rheumatoid arthritis (RA) treatment, variability in clinical response is often observed, with genetic polymorphisms to be referred as important. We aimed to elucidate the role of methylenetetrahydrofolate reductase (MTHFR) C677T and aminoimidazole carboxamide adenosine ribonucleotide transformylase (ATIC) T675C polymorphisms and clinicopathological variables in clinical response to MTX in Portuguese RA patients. Methods: Study included 233 RA patients treated with MTX for at least six months. Non-response was defined as a Disease Activity Score in 28 joints (DAS28) >3.2 in two consecutive evaluations. MTHFR C677T and ATIC T675C polymorphisms were genotyped and clinicopathological variables collected from all patients. Statistical analyses were performed and binary logistic regression method adjusted to possible confounding variables. Results: Multivariate analyses demonstrated that MTHFR 677TT (OR=4.63; P=0.013) and ATIC 675T carriers (OR=5.16; P=0.013) were associated with over 4-fold increased risk for non-response. Additionally, and considering clinicopathological variables, we observed that non-current smokers (OR=7.98; P=0.001), positivity to anti-cyclic citrullinated peptide (OR=3.53; P=0.004) and to antinuclear antibodies (OR=2.28; P=0.045), higher health assessment questionnaire score (OR=2.42; P=0.007) and non-steroidal anti-inflammatory drugs users (OR=2.77; P=0.018) were also associated with non-response. Contrarily, subcutaneous administration route (OR=0.11; P<0.001) was associated with response to MTX. Conclusion: Our study suggests that MTHFR C677T and ATIC T675C genotyping combined with clinicopathological data may help to identify patients whom will not benefit from MTX treatment and, therefore, assist clinicians to personalize RA treatment.
    BioMed Research International 05/2014; 2014(Article ID 368681):11 pages, 2014. · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sarcoidosis is a granulomatous disease which affects multiple organs. Its therapeutic management is very challenging due to the heterogeneity in disease manifestation and clinical course, as well as the potential side effects of the immunosuppressive therapy. An overview of presently available second-line and third-line systemic agents is provided.
    Current opinion in pulmonary medicine 07/2014; · 2.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Stratified medicine approaches for the treatment of musculoskeletal disorders offer opportunities to effectively target interventions to those individuals who will gain most benefit from them and minimise adverse side effects. Such approaches have been the 'holy grail' of a variety of research fields spanning epidemiological, (epi)genetic, transcriptomic, proteomic and imaging biomarkers that predict disease diagnosis, prognosis or response to treatment. In this review, we highlight the successes and opportunities for stratified medicine approaches across a range of musculoskeletal disorders, with a focus on genetic risk factors, since these are the most stable across the lifetime of each individual.
    Current Opinion in Pharmacology 05/2014; 16C:127-132. · 4.23 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014